Health
Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy – News-Medical.net
The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice….
A team of scientists from the United States has recently developed a formulation of toll-like receptor 9 (TLR9) agonist and aluminum hydroxide to increase the immunogenicity of spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.
…
-
Business22 hours agoWhat I’d buy if I had to invest $20,000 in ASX 200 shares before the weekend
-
General21 hours agoFederal government funding extends cohealth GP services until July 2026
-
Noosa News19 hours agoSunshine Coast Airport receives green light for major upgrade opening doors to growth jobs and tourism across the region
-
General5 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls